Literature DB >> 23340162

Histone-deacetylase inhibitors produce positive results in the GADD45a-GFP GreenScreen HC assay.

Donna Johnson1, Richard Walmsley.   

Abstract

Histone-deacetylase inhibitors (HDACi) are able to induce cell-cycle arrest, apoptosis and differentiation in a variety of tumour cell lines. The mechanisms leading to these cellular outcomes are not fully understood, however, it is has been proposed that induction of cell-cycle arrest might be a result of genotoxic stress. Despite the potential for genotoxic activity of this class of compounds, there are very few data available to provide evidence for this, either in vitro or in vivo. In this study, four HDACi, viz. trichostatin A, sodium butyrate, APHA compound 8 and apicidin, were tested in the human lymphoblastoid TK6 cell line-hosted GADD45a-GFP assay, which has high sensitivity and specificity in the detection of genotoxic carcinogens and in vivo genotoxicants. All four compounds produced positive genotoxicity results within the acceptable toxic dose range of the assay, with APHA compound 8 producing the weakest response. Taken alongside recent evidence demonstrating that GADD45a is not induced by non-genotoxic apoptogens, this study suggests that genotoxicity contributes to the anti-tumour activity of HDACi drugs.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340162     DOI: 10.1016/j.mrgentox.2012.12.009

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  4 in total

1.  Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?

Authors:  Sida Shen; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2015-11-25       Impact factor: 3.466

2.  QSAR ligand dataset for modelling mutagenicity, genotoxicity, and rodent carcinogenicity.

Authors:  Davy Guan; Kevin Fan; Ian Spence; Slade Matthews
Journal:  Data Brief       Date:  2018-02-02

Review 3.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

4.  HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines.

Authors:  Tobias S Iveland; Lars Hagen; Animesh Sharma; Mirta M L Sousa; Antonio Sarno; Kristian Lied Wollen; Nina Beate Liabakk; Geir Slupphaug
Journal:  J Transl Med       Date:  2020-04-07       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.